GALECTIN THERAPEUTICS INC. - COMMON STOCK

1,3900

02-мая-25 16:45:00

15 мин. задержка

Акции

+0,0900

+6,92%

Сегодняшний диапазон

1,3039 - 1,3950

ISIN

N/A

Источник

NASDAQ

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress

15 апр 2025 08:00:01 Источник Nasdaq GlobeNewswire
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

31 мар 2025 08:00:00 Источник Nasdaq GlobeNewswire
Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial

18 фев 2025 08:00:00 Источник Nasdaq GlobeNewswire
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

10 янв 2025 08:00:00 Источник Nasdaq GlobeNewswire
NetDania - New 12 months Low: GALECTIN THERAPEUTICS INC. - COMMON STOCK

20 дек 2024 10:16:30 Источник NetDania Notify
Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

20 дек 2024 08:00:00 Источник Nasdaq GlobeNewswire
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

18 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

14 ноя 2024 08:00:01 Источник Nasdaq GlobeNewswire
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

15 окт 2024 08:00:01 Источник Nasdaq GlobeNewswire
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference

30 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

03 сен 2024 08:30:00 Источник Nasdaq GlobeNewswire
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update

13 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer

01 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress

04 июн 2024 08:00:00 Источник Nasdaq GlobeNewswire
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update

15 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference

13 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis

09 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

29 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

12 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire
UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

13 ноя 2023 08:45:52 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.